Iskra Pusic, MD, MSCI

Bone Marrow Transplant Specialist, Medical Oncologist

Iskra Pusic

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Iskra Pusic, MD

Watch video on YouTube

Iskra Pusic, MD

4 mins

Iskra Pusic, MD Bone Marrow Transplant Specialist, Medical Oncologist at Siteman Cancer Center shares about their area of expertise.

Clinical Expertise

  • Bone marrow transplantation, graft-versus-host disease, leukemia, myelodysplastic syndrome.

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, WashU Medicine

Board Certification

  • 2008: American Board of Internal Medicine, Medical Oncology
  • 2009: American Board of Internal Medicine, Hematology

Training

  • 1997 - 1998: Intern, University Hospital Center, Zagreb, Croatia
  • 2001 - 2004: Resident, Internal Medicine, State University of New York Downstate Medical Center, New York, NY
  • 2004 - 2007: Fellow, Hematology and Oncology, State University of New York Downstate Medical Center, New York, NY
  • 2007 - 2008: Fellow, Bone Marrow Transplantation and Leukemia, WashU Medicine, St. Louis, MO

Education

  • 1997: MD, University of Zagreb, Zagreb, Croatia
  • 2015: MS, WashU Medicine, St. Louis, MO

Research & Selected Publications

Research Interest

Hematologic malignancies, stem cell transplantation and graft-versus-host disease.

Research Publications

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
Authors:

Lee SJ, Logan B, Horowitz MM, one or more additional authors omitted Pusic I, one or more additional authors omitted Ciurea SO

Journal & Year:

J Clin Oncol | 2025

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned
Authors:

El Jurdi N, Holtzman NG, Hishmeh R, one or more additional authors omitted Pusic I

Journal & Year:

Br J Haematol | 2025

Severe Aortic Stenosis and Chronic Myeloid Leukemia: Considerations for Valve Management
Authors:

Cunningham R, Yoo SGK, Brescia AA, one or more additional authors omitted Pusic I, Mitchell JD

Journal & Year:

JACC CardioOncol | 2025

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted Pusic I, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
Authors:

Jacoby MA, Duncavage ED, Khanna A, one or more additional authors omitted Pusic I, one or more additional authors omitted Walter MJ

Journal & Year:

Leukemia | 2025

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
Authors:

Wolff D, Cutler C, Lee SJ, Pusic I, one or more additional authors omitted Kitko CL

Journal & Year:

N Engl J Med | 2024

CML and the WHO: Why?
Authors:

Berman E, Shah NP, Deninger M, one or more additional authors omitted Pusic I, one or more additional authors omitted Druker B

Journal & Year:

J Clin Oncol | 2024

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Authors:

Shah NP, Bhatia R, Altman JK, one or more additional authors omitted Pusic I, one or more additional authors omitted Gregory K

Journal & Year:

J Natl Compr Canc Netw | 2024